NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Pediatrics Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group
The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydrogen sulfate).